
Understanding Depression Treatment Options in Quebec
A stepped-care, evidence-based guide to therapy, programs, medication, and specialized treatments
Written by Gio Arcuri, OT, MSc
Mental Health Occupational Therapist
Course Lecturer, McGill University
Fonder of Clinique Vivago
Depression treatment isn’t one single thing. In Quebec, care can range from weekly therapy to intensive outpatient programs, medication strategies, and hospital-based options like neuromodulation or ECT. The best choice is rarely “the strongest treatment.” It’s the right level of care, at the right time, with the ability to adjust as your needs change.
This pillar page is organized using stepped-care—a widely recommended framework in mental health systems that helps match treatment intensity to current needs, monitor response, and “step up” or “step down” when appropriate.
Medical disclaimer: This page is educational and not a medical diagnosis or a substitute for individualized care. If you are in immediate danger or at risk of self-harm, seek urgent help (911 or local emergency services).
Depression care in Quebec:
Why “level of care” matters
Depression affects not only mood, but sleep, motivation, concentration, appetite, energy, and the ability to function in daily life. When functioning starts to break down, treatment often needs more structure and coordination than weekly sessions can provide.
That’s why modern systems increasingly organize depression care as a pathway rather than a single intervention.

Stepped-care: the evidence-based framework behind “meeting you where you are”
Stepped-care is a structured approach that:
-
starts with the least intensive effective option,
-
monitors symptoms and functioning,
-
and adjusts care intensity as needed.
It’s designed to reduce under-treatment (staying too low-intensity when things are worsening) and over-treatment (unnecessarily high-intensity care when it’s not needed). Quebec health technology and guideline bodies have evaluated stepped approaches in depression contexts and related interventions used in stepped-care pathways.
Measurement + flexibility are the point
A stepped-care approach works best when programs track outcomes over time (symptoms + functional indicators like sleep routine, work/school participation, self-care, and relapse patterns).
References:
-
World Health Organization. (2017). Depression and other common mental disorders: Global health estimates. WHO. https://www.who.int/publications/i/item/depression-global-health-estimates
-
Bower, P., & Gilbody, S. (2005). Stepped care in psychological therapies: Access, effectiveness and efficiency. British Journal of Psychiatry, 186(1), 11–17. https://doi.org/10.1192/bjp.186.1.11
-
Karyotaki, E., et al. (2021). Efficacy of psychological interventions for depression in routine practice: A meta-analysis. The Lancet Psychiatry, 8(7), 572–584. https://doi.org/10.1016/S2215-0366(21)00110-8

The Vivago Stepped-Care Model:
Our adapted approach
Vivago’s stepped-care model applies the same principles, but anchors decisions in functional recovery—how depression is affecting everyday life, not only symptom checklists.
What “meeting you where you are” looks like in practice
-
Right-fit entry point: start at the level that matches current functioning and risk.
-
Interdisciplinary coordination: psychotherapy + occupational therapy + (when indicated) psychiatry, with shared goals and real-life practice.
-
Step-up without shame: if weekly therapy isn’t enough, the model escalates intensity rather than repeating the same approach indefinitely.
-
Step-down with support: as stability returns, care transitions intentionally to prevent relapse (aftercare, follow-ups, routine planning).
-
Neurodiversity-affirming adaptation: strategies are tailored to sensory, cognitive, and regulation differences (not forcing a single “normal” recovery template).
References
-
National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NG222). NICE. https://www.nice.org.uk/guidance/ng222
-
Canadian Agency for Drugs and Technologies in Health. (2016). Stepped care models in mental health. CADTH. https://www.cadth.ca/stepped-care-models-mental-health
-
Richards, D. A., & Borglin, G. (2011). Implementation of psychological therapies for anxiety and depression: The IAPT experience. Journal of Mental Health, 20(4), 318–327. https://doi.org/10.3109/09638237.2011.608746

Treatment options by level of care:
The Vivago stepped-care ladder
Level 1 — Interdisciplinary outpatient care led by occupational therapy
(when safety is stable, but daily functioning is becoming difficult)
In many care models, Step 1 is described as “weekly therapy.”
At Vivago, Step 1 is not therapy-only. It is an interdisciplinary, occupational therapy–led level of care focused on stabilizing daily functioning early, before difficulties escalate.
Depression often first shows up not as crisis, but as functional breakdown: disrupted sleep, loss of routine, difficulty initiating tasks, reduced self-care, withdrawal from work or school, and growing avoidance of daily responsibilities. When these changes begin, the most effective intervention is not insight alone, but practical, structured support in everyday life. (WHO, 2017; Fried & Nesse, 2014)
For this reason, occupational therapy is the driving force at Step 1 at Vivago, with psychotherapy and psychiatry integrated as complementary supports when indicated.
What occupational therapy leads at Step 1
Occupational therapy at Step 1 focuses on how depression is affecting day-to-day living, and on restoring the conditions that allow a person to function, participate, and regain momentum. (CAOT, 2018; AOTA, 2020)
At this level of care, occupational therapists work on (Eklund & Argentzell, 2016; Kielhofner, 2008):
-
Stabilizing daily routines
(sleep–wake cycle, meals, hygiene, weekly rhythm)
-
Supporting initiation and follow-through
when motivation, energy, or executive functioning are impaired
-
Managing energy and activity balance
to reduce cycles of overexertion and collapse
-
Maintaining participation in work, school, or caregiving roles
through graded adaptations rather than all-or-nothing decisions
-
Reducing avoidance of daily activities
that have become overwhelming or emotionally loaded
-
Applying emotional regulation strategies in real contexts
(at home, during transitions, in daily tasks)
The focus is always practical and observable:
What is no longer happening in daily life — and how do we help it restart in a sustainable way?
How evidence-based frameworks are used within occupational therapy
(not psychotherapy)
At Vivago, occupational therapists use evidence-informed frameworks to guide how activities, routines, and environments are structured — not to provide psychotherapy.
These frameworks inform what we support people to do, not how we treat thoughts or emotions in isolation. (Brown & Stoffel, 2011; Hayes et al., 2012; Dimidjian et al., 2006)
ACT-informed (Acceptance and Commitment–informed) support
Occupational therapists use ACT-informed principles to help people re-engage in meaningful activities despite low mood or distress, rather than waiting for symptoms to resolve.
This may involve:
-
clarifying what matters to the person in daily life,
-
identifying how depression has narrowed participation,
-
supporting values-consistent action in small, realistic steps.
The goal is participation, not emotional processing.
CBT-informed (Cognitive Behavioral–informed) strategies
CBT-informed approaches are used to understand behavior–function relationships, especially through behavioral activation and routine restructuring. (Dimidjian et al., 2006; Ekers et al., 2014)
In occupational therapy, this means:
-
mapping how inactivity, avoidance, and low structure reinforce functional decline,
-
designing activity-based experiments in daily life,
-
supporting task initiation and completion through environmental and routine changes.
The emphasis is on doing differently, not on cognitive restructuring.
DBT-informed tools for regulation in daily life
DBT-informed skills are used to support emotional regulation and distress tolerance in everyday situations, such as mornings, transitions, or socially demanding tasks. (Linehan, 2015; Brown & Stoffel, 2011)
Occupational therapists help people:
-
recognize early signs of dysregulation during daily routines,
-
apply regulation strategies in the moment, in real environments,
-
adapt strategies to sensory and cognitive needs.
This is skills application, not psychotherapy.
Graded exposure through daily activities
Occupational therapy frequently uses graded exposure to help people re-enter avoided activities safely. (Craske et al., 2014; Creek, 2003)
This may include:
-
gradually returning to tasks like leaving the house, checking emails, or attending meetings,
-
breaking activities into manageable steps,
-
supporting exposure in real-world contexts, with pacing and recovery built in.
The focus is on restoring participation, not treating fear responses in isolation.
The role of psychotherapy and psychiatry at Step 1
-
Psychotherapy, when included, supports emotional insight, processing, and relational patterns — and is integrated with occupational therapy goals rather than operating separately.
-
Psychiatry is involved selectively and strategically, when medication assessment or adjustment is indicated, with attention to functional outcomes (sleep, energy, daily participation). (WHO, 2017; Eklund & Argentzell, 2016)
Care is coordinated so that everyone is working toward the same functional objectives.
Why this model matters
An occupational therapy–led Step 1:
-
addresses problems before they become crises,
-
reduces the risk of under- or over-treatment,
-
provides a clear signal when higher-intensity care is needed,
-
and helps people regain traction in daily life early.
When Step 1 is done well, stepping up to more intensive care is a clinical adjustment, not a failure.
References
-
American Occupational Therapy Association. (2020). Occupational therapy practice guidelines for adults with serious mental illness. AOTA Press.
-
Brown, C., & Stoffel, V. C. (2011). Occupational therapy in mental health: A vision for participation. F.A. Davis.
-
Canadian Association of Occupational Therapists. (2018). Position statement: Occupational therapy and mental health. CAOT. https://caot.ca
-
Creek, J. (2003). Occupational therapy defined as a complex intervention. British Journal of Occupational Therapy, 66(5), 210–218. https://doi.org/10.1177/030802260306600503
-
Craske, M. G., Treanor, M., Conway, C. C., Zbozinek, T., & Vervliet, B. (2014). Maximizing exposure therapy: An inhibitory learning approach. Behaviour Research and Therapy, 58, 10–23. https://doi.org/10.1016/j.brat.2014.04.006
-
Dimidjian, S., Hollon, S. D., Dobson, K. S., Schmaling, K. B., Kohlenberg, R. J., Addis, M. E., … Jacobson, N. S. (2006). Behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of major depression. Journal of Consulting and Clinical Psychology, 74(4), 658–670. https://doi.org/10.1037/0022-006X.74.4.658
-
Ekers, D., Webster, L., Van Straten, A., Cuijpers, P., Richards, D., & Gilbody, S. (2014). Behavioural activation for depression: An update of meta-analysis. World Psychiatry, 13(3), 318–327. https://doi.org/10.1002/wps.20162
-
Eklund, M., & Argentzell, E. (2016). Perceived occupational balance and well-being among people with mental illness. Scandinavian Journal of Occupational Therapy, 23(4), 252–259. https://doi.org/10.3109/11038128.2015.1102969
-
Fried, E. I., & Nesse, R. M. (2014). The impact of individual depressive symptoms on impairment of psychosocial functioning. PLoS Medicine, 11(2), e1001686. https://doi.org/10.1371/journal.pmed.1001686
-
Hayes, S. C., Strosahl, K. D., & Wilson, K. G. (2012). Acceptance and Commitment Therapy: The process and practice of mindful change (2nd ed.). Guilford Press.
-
Kielhofner, G. (2008). Model of Human Occupation: Theory and application (4th ed.). Lippincott Williams & Wilkins.
-
Linehan, M. M. (2015). DBT skills training manual (2nd ed.). Guilford Press.
-
World Health Organization. (2017). Depression and other common mental disorders: Global health estimates. WHO. https://www.who.int/publications/i/item/depression-global-health-estimates
Level 2 — Intensive interdisciplinary outpatient programs
(when functioning is significantly compromised, without indication for hospitalization)
Level 2 is indicated when daily functioning continues to deteriorate despite lower-intensity outpatient care. At this stage, individuals may not be in acute crisis, but experience a persistent disruption of daily life: loss of routine, inability to maintain roles, generalized avoidance, exhaustion, and increasing rigidity in coping strategies.
At Vivago, Level 2 takes the form of intensive interdisciplinary outpatient programs, structured around functional recovery, with close coordination across professions and ongoing adjustment of care intensity (Bower & Gilbody, 2005; Kallert et al., 2007).
The central role of occupational therapy at Level 2
Within intensive programs, occupational therapy remains a structuring pillar of care:
-
establishing a therapeutic weekly rhythm (regular attendance, temporal anchoring);
-
repeated practice in real-life contexts of regulation, organization, and participation strategies;
-
active support for the resumption of meaningful occupations (work, studies, relationships, self-care);
-
continuous observation of functioning to rapidly adjust interventions or intensity.
Occupational therapy acts as a connecting thread across interventions, ensuring coherence between what is addressed in sessions and what unfolds in everyday life (Kielhofner, 2008; Eklund & Argentzell, 2016).
Contribution of other professionals at Level 2
Level 2 relies on true interdisciplinarity, with each profession intervening within its scope of practice:
-
Psychology / psychotherapy: support for emotional, cognitive, relational, and identity-related processes, aligned with functional goals;
-
Psychiatry: clinical assessment when indicated, medication adjustment, and monitoring treatment effects in relation to functioning;
-
Social work: support for psychosocial, family, financial, academic, or vocational challenges, and assistance during transitions;
-
Sex therapy / sexology: intervention when depression impacts sexuality, intimacy, identity, or relationships — domains often central to well-being and recovery;
-
Other health professionals, as needed (e.g., nutrition, neuropsychology).
The goal is not parallel care, but the active co-construction of an integrated plan, continuously adjusted based on functional evolution (Priebe et al., 2011).
Level 3 — Hospital-based and specialized care
(when safety, stability, or overall health is compromised)
Level 3 is indicated when safety cannot be ensured, suicidal risk is high, or medical or psychiatric stabilization is required. This level includes hospitalization, emergency services, and certain specialized interventions.
Within a stepped-care approach, Level 3 is not an endpoint, but a transitional phase within a broader care pathway. Evidence shows that outcomes improve when hospitalization is paired with structured planning for return to intensive outpatient care, rather than abrupt discharge to minimal services (Olfson et al., 2016; Vigod et al., 2015).
Maintaining functional continuity during hospitalization
Even when care is hospital-based, the central question remains:
How will the person resume daily life after stabilization?
At Vivago, Level 3 is conceptualized in relation to:
-
a gradual return to Level 2 or Level 1 care;
-
rebuilding daily routines;
-
active relapse prevention;
-
close coordination with hospital and community-based teams.
This continuity reduces care fragmentation, early readmission risk, and the experience of “starting from zero” after discharge (Vigod et al., 2015; Heggestad, 2002).
References — Levels 2 and 3
Bower, P., & Gilbody, S. (2005). Stepped care in psychological therapies: Access, effectiveness and efficiency. British Journal of Psychiatry, 186(1), 11–17. https://doi.org/10.1192/bjp.186.1.11
Eklund, M., & Argentzell, E. (2016). Perceived occupational balance and well-being among people with mental illness. Scandinavian Journal of Occupational Therapy, 23(4), 252–259. https://doi.org/10.3109/11038128.2015.1102969
Heggestad, T. (2002). Do hospital length of stay and staffing predict readmission? Social Psychiatry and Psychiatric Epidemiology, 37, 213–219. https://doi.org/10.1007/s00127-002-0531-9
Kallert, T. W., et al. (2007). Effectiveness of inpatient versus outpatient treatment for depression. British Journal of Psychiatry, 191, 427–435. https://doi.org/10.1192/bjp.bp.106.035972
Kielhofner, G. (2008). Model of Human Occupation: Theory and application (4th ed.). Lippincott Williams & Wilkins.
Olfson, M., et al. (2016). Short-term outcomes of psychiatric hospitalization. Psychiatric Services, 67(10), 1119–1125. https://doi.org/10.1176/appi.ps.201500358
Priebe, S., et al. (2011). Effectiveness of structured outpatient care compared with inpatient treatment. British Journal of Psychiatry, 199(1), 47–52. https://doi.org/10.1192/bjp.bp.110.087502
Vigod, S. N., et al. (2015). Transitional interventions to reduce early psychiatric readmissions. American Journal of Psychiatry, 172(6), 515–524. https://doi.org/10.1176/appi.ajp.2014.14070878

Evidence-based psychotherapy options, including integrative approaches)
The Vivago Signature — Our approach
At Vivago, depression is understood as a disruption of functioning, not only of mood.
Our stepped-care model is anchored in strong occupational therapy, integrated within true interdisciplinary care that includes psychology, psychiatry, social work, sex therapy, and other professional expertise as needed.
We adjust care intensity at the right time, without fragmentation, prioritizing participation in daily life, dignity, and sustainable recovery.
CBT, Behavioral Activation, IPT (first-line psychotherapies)
These are common, evidence-based options that target thinking patterns, behavior/routine, and interpersonal functioning.
EMDR (when depression is trauma-linked)
EMDR is best established for trauma-related conditions and is often used when depression is intertwined with traumatic stress or adverse experiences (as part of an integrated plan).
References
-
van der Kolk, B. A., et al. (2007). A randomized clinical trial of EMDR. Journal of Clinical Psychiatry, 68(1), 37–46.
-
Carletto, S., et al. (2017). EMDR for depression: A systematic review. Frontiers in Psychology, 8, 1654. https://doi.org/10.3389/fpsyg.2017.01654
Clinical hypnosis (adjunctive)
Hypnosis is generally positioned as an adjunct (e.g., for anxiety, sleep, pain, somatic symptoms, and regulation), not a standalone treatment for major depression.
References
-
Alladin, A. (2012). Cognitive hypnotherapy for depression. International Journal of Clinical and Experimental Hypnosis, 60(2), 114–135. https://doi.org/10.1080/00207144.2012.648070
-
Milling, L. S., et al. (2018). Hypnosis as an adjunct to psychotherapy: A meta-analysis. American Journal of Clinical Hypnosis, 61(1), 1–26. https://doi.org/10.1080/00029157.2018.1444036

Medication options from first-line treatment to augmentation
Medication is commonly part of depression care in Quebec, typically through family physicians, GMFs, psychiatrists, or hospital outpatient clinics.
SSRIs and SNRIs (common first-line options)
-
SSRIs and SNRIs are widely used first-line antidepressants.
-
Response varies, and many guidelines emphasize shared decision-making, side-effect monitoring, and functional outcomes (not just symptom score changes).
Augmentation and combination strategies
When depression is partially responsive or treatment-resistant, prescribers may consider:
-
SSRI/SNRI + atypical antipsychotic augmentation (e.g., aripiprazole or quetiapine in select cases)
-
other augmentation strategies depending on clinical history and tolerability
These strategies have evidence in treatment-resistant depression, but require careful monitoring due to metabolic/sedation and other risks.
References:
-
Cipriani, A., et al. (2018). Comparative efficacy and acceptability of antidepressants for major depressive disorder. The Lancet, 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
-
Rush, A. J., et al. (2006). Acute and longer-term outcomes in STAR*D. American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
-
Nelson, J. C., & Papakostas, G. I. (2009). Atypical antipsychotic augmentation in major depressive disorder. American Journal of Psychiatry, 166(9), 980–991. https://doi.org/10.1176/appi.ajp.2009.09030312

Neuromodulation & hospital-based procedures: Specialized care
rTMS / SMTr (Repetitive Transcranial Magnetic Stimulation)
rTMS (SMTr in French) is a non-invasive neuromodulation treatment used in treatment-resistant depression. In Quebec, it exists in specialized settings, and INESSS has published work on its use and evaluation in the province.
Examples of Quebec access points:
-
CHUM — Psychiatric Neuromodulation Clinic (requires referral by a treating psychiatrist)
-
CISSS/CIUSSS services offering neuromodulation may exist regionally (availability varies; referral routes differ). One example of a regional neuromodulation clinic is available through Santé Montérégie.
References:
-
Institut national d’excellence en santé et en services sociaux. (2026). Stimulation magnétique transcrânienne répétée pour la dépression réfractaire. INESSS. https://www.inesss.qc.ca
-
Lefaucheur, J. P., et al. (2020). Evidence-based guidelines on the therapeutic use of rTMS. Clinical Neurophysiology, 131(2), 474–528. https://doi.org/10.1016/j.clinph.2019.11.002
ECT / sismothérapie (Electroconvulsive Therapy)
ECT is a highly effective hospital-based treatment for severe or treatment-resistant depression in specific indications and is delivered under anesthesia. Quebec public bodies describe it as an “exception” treatment with regional variation in availability.
Examples of Quebec access points (public/hospital-based):
-
CHUM — ECT expertise page
-
Institut universitaire en santé mentale Douglas — sismotherapy (ECT) clinic page
-
IUSMM / Institut universitaire en santé mentale de Montréal is referenced in Quebec materials about ECT services and collaboration (and is commonly associated with ECT services in Quebec).
Availability can vary by region and hospital; access is typically through psychiatry/hospital referral pathways.
References
-
UK ECT Review Group. (2003). Efficacy and safety of electroconvulsive therapy. The Lancet, 361(9360), 799–808. https://doi.org/10.1016/S0140-6736(03)12705-5
-
Institut national de santé publique du Québec. (2019). Utilisation de l’électroconvulsivothérapie chez les adultes au Québec. INSPQ. https://www.inspq.qc.ca

Rapid-acting / emerging options for treatment-resistant depression
Ketamine (IV/IM) in Quebec
Quebec’s health system has evaluated ketamine’s role in treatment-resistant depression, and INESSS published an opinion framing it as an exceptional treatment in specific contexts.
Example of a public specialized pathway:
-
Douglas — Ketamine treatment clinic (in the context of severe/treatment-resistant depressive disorders; access via psychiatrist referral and active mental health follow-up)
Example of private availability (varies, verify protocols and medical oversight):
-
Private clinics in Montreal advertise ketamine services; quality and protocols vary, so patients should ask about medical supervision, indication criteria, and integration with psychotherapy.
Clinical innovation note (Montreal):
McGill-affiliated reporting has described research suggesting ketamine benefits may be enhanced by combining it with psychotherapy and supportive treatment contexts.
Esketamine (Spravato)
Esketamine is discussed in evidence reviews for treatment-resistant depression; access generally requires structured medical supervision and specific eligibility. (This is not the same as “at-home ketamine.”)
References:
-
Wilkinson, S. T., et al. (2018). Ketamine as a treatment for depression. American Journal of Psychiatry, 175(4), 327–335. https://doi.org/10.1176/appi.ajp.2017.17040472
-
Institut national d’excellence en santé et en services sociaux. (2023). Kétamine et dépression réfractaire aux traitements. INESSS. https://www.inesss.qc.ca
-
Canadian Agency for Drugs and Technologies in Health. (2021). Esketamine (Spravato) for treatment-resistant depression. CADTH. https://www.cadth.ca
Psychedelic-assisted therapy (psilocybin, MDMA): where it stands in Canada/Quebec
In Canada, access to psilocybin and MDMA for therapeutic purposes is generally limited to clinical trials or Health Canada’s Special Access Program (SAP) under specific circumstances; Health Canada has described SAP pathways and exemptions related to these substances.
What this means practically in Quebec:
-
These treatments are not routine standard-of-care for depression.
-
Some access may occur via research trials or SAP requests led by qualified clinicians, when other options have failed and safeguards are met.
References:
-
Carhart-Harris, R. L., et al. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
-
Mitchell, J. M., et al. (2021). MDMA-assisted therapy for PTSD. Nature Medicine, 27, 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
-
Health Canada. (2022). Special Access Program: Psychedelic-assisted psychotherapy. https://www.canada.ca

How to choose a depression program:
Questions that matter in Quebec
1) Can the program step up or step down without fragmentation?
Look for clear pathways (weekly → intensive outpatient programs → step-down aftercare), not siloed episodes.
2) Is psychiatry integrated or coordinated?
Ask:
-
Do you have psychiatric assessment access if needed?
-
Who coordinates medication + therapy goals?
-
What’s the referral route if symptoms worsen?
3) What does aftercare look like?
Strong programs plan:
-
transition sessions
-
relapse prevention
-
maintenance routines
-
follow-up scheduling and accountability
4) Is it neurodiversity-affirming?
Ask:
-
Are strategies adapted for sensory overload, executive function, and different communication styles?
-
Does the program avoid one-size-fits-all productivity norms?

Quebec-specific access: RAMQ vs private
What people usually need to know
Public system (RAMQ)
-
Hospital-based care (inpatient psychiatry, emergency stabilization) is typically within public pathways.
-
Access to specialized treatments like ECT, rTMS, or ketamine in public settings often requires psychiatrist referral and depends on program criteria and regional availability (examples above).
Private system (insurance / out-of-pocket)
-
Psychotherapy and allied health services may be reimbursed by private insurance depending on the provider type and plan.
-
Many people use private care to reduce wait times, access specialized modalities, and build an intensive plan with continuity.

References
Alladin, A. (2012). Cognitive hypnotherapy for depression: An integrative approach. International Journal of Clinical and Experimental Hypnosis, 60(2), 114–135. https://doi.org/10.1080/00207144.2012.648070
Barth, J., Munder, T., Gerger, H., Nüesch, E., Trelle, S., Znoj, H., … Cuijpers, P. (2013). Comparative efficacy of seven psychotherapeutic interventions for patients with depression: A network meta-analysis. PLoS Medicine, 10(5), e1001454. https://doi.org/10.1371/journal.pmed.1001454
Bower, P., & Gilbody, S. (2005). Stepped care in psychological therapies: Access, effectiveness and efficiency. British Journal of Psychiatry, 186(1), 11–17. https://doi.org/10.1192/bjp.186.1.11
Canadian Agency for Drugs and Technologies in Health. (2016). Stepped care models in mental health. https://www.cadth.ca/stepped-care-models-mental-health
Canadian Agency for Drugs and Technologies in Health. (2021). Esketamine (Spravato) for treatment-resistant depression. https://www.cadth.ca
Carhart-Harris, R. L., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., … Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
Carletto, S., Ostacoli, L., Colombi, N., Calorio, L., Oliva, F., Fernandez, I., & Hofmann, A. (2017). EMDR for depression: A systematic review. Frontiers in Psychology, 8, 1654. https://doi.org/10.3389/fpsyg.2017.01654
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., … Geddes, J. R. (2018). Comparative efficacy and acceptability of antidepressants for major depressive disorder. The Lancet, 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
Cuijpers, P., van Straten, A., Andersson, G., & van Oppen, P. (2013). Psychotherapy for depression in adults: A meta-analysis of comparative outcome studies. Journal of Consulting and Clinical Psychology, 81(6), 1045–1057. https://doi.org/10.1037/a0034490
Ekers, D., Webster, L., van Straten, A., Cuijpers, P., Richards, D., & Gilbody, S. (2014). Behavioural activation for depression: An update of meta-analysis. World Psychiatry, 13(3), 318–327. https://doi.org/10.1002/wps.20162
Health Canada. (2022). Special Access Program: Psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products
Heggestad, T. (2002). Do hospital length of stay and staffing predict readmission? Social Psychiatry and Psychiatric Epidemiology, 37, 213–219. https://doi.org/10.1007/s00127-002-0531-9
Institut national d’excellence en santé et en services sociaux. (2023). Kétamine et dépression réfractaire aux traitements. Gouvernement du Québec. https://www.inesss.qc.ca
Institut national d’excellence en santé et en services sociaux. (2026). Stimulation magnétique transcrânienne répétée pour la dépression réfractaire aux traitements chez l’adulte. Gouvernement du Québec. https://www.inesss.qc.ca
Institut national de santé publique du Québec. (2019). Utilisation de l’électroconvulsivothérapie chez les adultes au Québec. https://www.inspq.qc.ca
Kallert, T. W., Priebe, S., McCabe, R., Kiejna, A., Rymaszewska, J., Nawka, P., … Kjellin, L. (2007). Effectiveness of inpatient versus outpatient treatment for depression. British Journal of Psychiatry, 191, 427–435. https://doi.org/10.1192/bjp.bp.106.035972
Karyotaki, E., Efthimiou, O., Miguel, C., Bermpohl, F. M. G., Furukawa, T. A., Cuijpers, P., … Driessen, E. (2021). Efficacy of psychological interventions for depression in routine practice: A meta-analysis. The Lancet Psychiatry, 8(7), 572–584. https://doi.org/10.1016/S2215-0366(21)00110-8
Lefaucheur, J.-P., Aleman, A., Baeken, C., Benninger, D. H., Brunelin, J., Di Lazzaro, V., … Ziemann, U. (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation. Clinical Neurophysiology, 131(2), 474–528. https://doi.org/10.1016/j.clinph.2019.11.002
Marshall, M., Crowther, R., Almaraz-Serrano, A., Creed, F., Sledge, W., Kluiter, H., … Tyrer, P. (2001). Day hospital versus admission for acute psychiatric disorders. Cochrane Database of Systematic Reviews, (2), CD004026. https://doi.org/10.1002/14651858.CD004026
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD. Nature Medicine, 27, 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NG222). https://www.nice.org.uk/guidance/ng222
Nelson, J. C., & Papakostas, G. I. (2009). Atypical antipsychotic augmentation in major depressive disorder. American Journal of Psychiatry, 166(9), 980–991. https://doi.org/10.1176/appi.ajp.2009.09030312
Olfson, M., Wall, M., Wang, S., Crystal, S., Gerhard, T., & Blanco, C. (2016). Short-term outcomes of psychiatric hospitalization. Psychiatric Services, 67(10), 1119–1125. https://doi.org/10.1176/appi.ps.201500358
Richards, D. A., & Borglin, G. (2011). Implementation of psychological therapies for anxiety and depression: The IAPT experience. Journal of Mental Health, 20(4), 318–327. https://doi.org/10.3109/09638237.2011.608746
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., … Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
UK ECT Review Group. (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders. The Lancet, 361(9360), 799–808. https://doi.org/10.1016/S0140-6736(03)12705-5
van der Kolk, B. A., Spinazzola, J., Blaustein, M. E., Hopper, J. W., Hopper, E. K., Korn, D. L., & Simpson, W. B. (2007). A randomized clinical trial of EMDR. Journal of Clinical Psychiatry, 68(1), 37–46.
Vigod, S. N., Kurdyak, P. A., Dennis, C.-L., Leszcz, T., Taylor, V. H., Blumberger, D. M., & Seitz, D. P. (2015). Transitional interventions to reduce early psychiatric readmissions. American Journal of Psychiatry, 172(6), 515–524. https://doi.org/10.1176/appi.ajp.2014.14070878
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., … Sanacora, G. (2018). Ketamine as a treatment for depression. American Journal of Psychiatry, 175(4), 327–335. https://doi.org/10.1176/appi.ajp.2017.17040472
World Health Organization. (2017). Depression and other common mental disorders: Global health estimates. https://www.who.int/publications/i/item/depression-global-health-estimates